• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Brand Quest
• The New Manager
• Smartbuy

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth
• Events 2007

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Hyderabad, Aug. 18

Suven Life Sciences Ltd has been granted the first Certificate of Suitability (CEP) by the European Directorate for the Quality of Medicines for its Active Pharmaceutical Ingredient (API), Tamsulosin Hydrochloride. The CEP would mean that the API of the Hyderabad-based company is suitable for use in medicinal products. It is recognised by the 36 member States of the European Union besides Australia, Canada and Switzerland.

CEP is used to certify the compliance of a material with the requirements laid down in the relevant monograph of the European Pharmacopoeia, according to a release. —

Our Bureau

More Stories on : Standards & Benchmarks | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Copyright © 2008, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line